Immune Thrombocytopenia
We recommend
How do patients perceive the treatment of ITP with romiplostim?
Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.
Central European Expert Consensus on the Treatment of ITP in Adult Patients
In a recently published consensus, experts from Central Europe evaluate the current treatment…
ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia
The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in…
Articles on this topic
Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia
Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an…
How TPO-RA Drugs Fared in Meta-Analyses of Safety and Efficacy in ITP Patients
Meta-analyses regarding the use of thrombopoietin receptor agonists (TPO-RA) evaluated their…
Romiplostim in Routine Clinical Use among Patients with ITP in European Countries − Fresh Data Analysis
Data from randomized clinical trials have shown that romiplostim is an effective medication…
Fatigue as a Significant Symptom of Immune Thrombocytopenia from the Patients' Perspective
The I-WISh survey assessed the impact of immune thrombocytopenia (ITP) and its treatment on…
Optimization of Romiplostim Administration in ITP Treatment
In their newly published review article, authors from several American institutions summarize…
Physiological and Clinical Effect of Romiplostim in the Treatment of ITP
Romiplostim in the treatment of immune thrombocytopenia (ITP) has demonstrated safety and the…
Administration of Romiplostim in Patients with ITP in Real-World Practice in Central Europe
Data from the PLATON study on the administration of romiplostim in real-world clinical…
Thrombocytopenia Following mRNA Vaccination Against SARS-CoV-2
In connection with the administration of mRNA-based vaccines against the SARS-CoV-2…
Options for Reducing or Discontinuing TPO-RA Therapy in ITP Patients − Expert Consensus
There are currently no clear recommendations regarding dose reduction or discontinuation of…
Summary of Recommendations for the Treatment of Immune Thrombocytopenia in Pregnancy
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a temporary or…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- COVID-19 and Immune Thrombocytopenic Purpura − Spanish Experience Suggests Surprising Connections
- Idiopathic Thrombocytopenic Purpura with SARS-CoV-2 Infection
- Thrombocytopenia Following mRNA Vaccination Against SARS-CoV-2
- Fatigue as a Significant Symptom of Immune Thrombocytopenia from the Patients' Perspective
- Summary of Recommendations for the Treatment of Immune Thrombocytopenia in Pregnancy
- Current ASH Guidelines on ITP Management 2019 – Recommendations for Newly Diagnosed ITP in Children
Journal on this topic
Related topic